NMN for Mild Cognitive Impairment: What the Evidence Actually Shows
What is Mild Cognitive Impairment?
Mild cognitive impairment is measurable cognitive decline beyond normal ageing but not severe enough to disrupt daily independence. A subset progresses to dementia each year.
NMN relevance: the published evidence
No published RCT has tested NMN in MCI. The Yoshino 2018 review notes the mechanistic case for NAD+ in brain ageing, but human cognitive endpoints remain untested. Patients with MCI should pursue cardiovascular control, sleep, hearing aids if needed, and structured cognitive activity.
Questions to ask before supplementing
No dose validated for MCI.
Contraindications and red flags
Pursue formal cognitive assessment; do not self-treat.
Bottom line for Malaysian patients
NMN is not registered with NPRA as a treatment for any specific condition; it is sold as a general health supplement. If you have mild cognitive impairment, use this page as a question list for a registered medical practitioner before adding NMN to existing therapy. Read our safety guide for full red-flag context.
Related conditions
- Alzheimer's Disease - Alzheimer's disease is the most common cause of dementia, marked by progressive memory loss, cogniti...
- Age-Related Cognitive Decline - Age-related cognitive decline is the gradual slowing of processing speed, memory and executive funct...
- Parkinson's Disease - Parkinson's disease is a progressive neurodegenerative disorder marked by tremor, rigidity, bradykin...
- Biological Aging - Biological aging refers to the gradual decline in cellular and organ function that accompanies chron...